Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 11/20 | 0.40 |
| ▸ | MEN1 | O00255 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | POLB | P06746 | 2/20 | 0.39 |
| ▸ | TTR | P02766 | 2/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | BLM | P54132 | 1/20 | 0.39 |
| ▸ | PLA2G1B | P04054 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | ATG4B | Q9Y4P1 | 1/20 | 0.39 |
| ▸ | NAT1 | P18440 | 1/20 | 0.36 |
| ▸ | MAOA | P21397 | 2/20 | 0.35 |
| ▸ | MAOB | P27338 | 2/20 | 0.35 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.35 |
| ▸ | PIM1 | P11309 | 1/20 | 0.35 |
| ▸ | PIM3 | Q86V86 | 1/20 | 0.35 |
| ▸ | PIM2 | Q9P1W9 | 1/20 | 0.35 |
| ▸ | IGF1R | P08069 | 1/20 | 0.34 |
| ▸ | TDP2 | O95551 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL497531 | 0.88 | NAT1 (0.39) | HPGDMEN1ALDH1A1KMT2APOLB | |
| SCHEMBL497021 | 0.88 | HPGD (0.32) | HPGDMEN1ALDH1A1KMT2APOLB | |
| SCHEMBL497245 | 0.84 | HPGD (0.46) | HPGDALDH1A1KMT2APOLBPTPN1 | |
| SCHEMBL496945 | 0.82 | MAPT (0.34) | HPGDMEN1ALDH1A1KMT2APOLB | |
| SCHEMBL4379161 | 0.82 | CDC25B (0.35) | HPGDALDH1A1KMT2APOLBPTPN1 | |
| SCHEMBL497129 | 0.82 | KMT2A (0.41) | HPGDMEN1ALDH1A1KMT2APOLB | |
| SCHEMBL2788176 | 0.81 | DYRK3 (0.35) | HPGDMEN1KMT2APOLBCASP6 | |
| SCHEMBL6064830 | 0.81 | NPC1 (0.31) | — | |
| SCHEMBL2788331 | 0.80 | MEN1 (0.44) | HPGDMEN1ALDH1A1KMT2APOLB | |
| SCHEMBL497261 | 0.78 | KMT2A (0.48) | HPGDMEN1ALDH1A1KMT2APOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 172 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4732908-A2 | CANCER TREATMENT USING COMBINATIONS OF ERK AND RAF INHIBITORS | Biomed Valley Discoveries, Inc. (US) | 2026-04-29 | — | — | EP | claimed |
| US-20260053785-A1 | COMBINATION THERAPY FOR TREATMENT OF CANCER | PMV PHARMACEUTICALS INC (US) | 2026-02-26 | — | — | US | claimed |
| EP-4043017-B1 | CANCER TREATMENT USING COMBINATIONS OF ERK AND RAF INHIBITORS | BIOMED VALLEY DISCOVERIES INC (US) | 2026-01-28 | — | — | EP | claimed |
| EP-3082423-B1 | CANCER TREATMENTS USING COMBINATIONS OF CDK AND ERK INHIBITORS | BIOMED VALLEY DISCOVERIES INC (US) | 2024-12-11 | — | — | EP | claimed |
| EP-4389225-A2 | CANCER TREATMENTS USING COMBINATIONS OF TYPE 2 MEK AND ERK INHIBITORS | Biomed Valley Discoveries, Inc. (US) | 2024-06-26 | — | — | EP | claimed |
| US-20230355678-A1 | METHODS FOR IMPROVING T CELL EFFICACY | Immatics US, Inc. | 2023-11-09 | — | — | US | claimed |
| US-11723923-B2 | Methods of preparing T cells for T cell therapy | KITE PHARMA, INC. (US) | 2023-08-15 | — | — | US | claimed |
| EP-3082779-B1 | CANCER TREATMENTS USING COMBINATIONS OF TYPE 2 MEK AND ERK INHIBITORS | BIOMED VALLEY DISCOVERIES INC (US) | 2023-06-07 | — | — | EP | claimed |
| EP-3082957-B1 | CANCER TREATMENTS USING COMBINATIONS OF PI3K/AKT PATHWAY AND ERK INHIBITORS | BIOMED VALLEY DISCOVERIES INC (US) | 2022-04-06 | — | — | EP | claimed |
| EP-3082800-B1 | CANCER TREATMENT USING COMBINATIONS OF ERK AND RAF INHIBITORS | BIOMED VALLEY DISCOVERIES INC (US) | 2022-02-02 | — | — | EP | claimed |
| EP-3082423-A1 | CANCER TREATMENTS USING COMBINATIONS OF CDK AND ERK INHIBITORS | Biomed Valley Discoveries, Inc. (US) | 2016-10-26 | — | — | EP | claimed |
| WO-2015095840-A1 | CANCER TREATMENTS USING COMBINATIONS OF CDK AND ERK INHIBITORS | BIOMED VALLEY DISCOVERIES, INC. (US) | 2015-06-25 | — | — | WO | claimed |
| WO-2015095842-A2 | METHODS AND COMPOSITIONS FOR TREATING NON-ERK MAPK PATHWAY INHIBITOR-RESISTANT CANCERS | BIOMED VALLEY DISCOVERIES, INC. (US) | 2015-06-25 | — | — | WO | claimed |
| WO-2015095831-A1 | CANCER TREATMENTS USING COMBINATIONS OF MTOR AND ERK INHIBITORS | BIOMED VALLEY DISCOVERIES, INC. (US) | 2015-06-25 | — | — | WO | claimed |
| WO-2015095834-A2 | CANCER TREATMENTS USING ERK1/2 AND BCL-2 FAMILY INHIBITORS | BIOMED VALLEY DISCOVERIES, INC. (US) | 2015-06-25 | — | — | WO | claimed |
| WO-2015095838-A2 | CANCER TREATMENTS USING COMBINATIONS OF MEK TYPE I AND ERK INHIBITORS | BIOMED VALLEY DISCOVERIES, INC. (US) | 2015-06-25 | — | — | WO | claimed |
| WO-2015095819-A2 | CANCER TREATMENT USING COMBINATIONS OF ERK AND RAF INHIBITORS | BIOMED VALLEY DISCOVERIES, INC. (US) | 2015-06-25 | — | — | WO | claimed |
| WO-2015095807-A1 | CANCER TREATMENTS USING COMBINATIONS OF EGFR AND ERK INHIBITORS | BIOMED VALLEY DISCOVERIES, INC. (US) | 2015-06-25 | — | — | WO | claimed |
| WO-2015095829-A1 | CANCER TREATMENTS USING COMBINATIONS OF PI3K/AKT PATHWAY AND ERK INHIBITORS | BIOMED VALLEY DISCOVERIES, INC. (US) | 2015-06-25 | — | — | WO | claimed |
| WO-2015095825-A1 | CANCER TREATMENTS USING COMBINATIONS OF TYPE 2 MEK AND ERK INHIBITORS | BIOMED VALLEY DISCOVERIES, INC. (US) | 2015-06-25 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260053785-A1 | COMBINATION THERAPY FOR TREATMENT OF CANCER | TP53, PI4K2A, PIK3CA | HPGD 4558/4885MEN1 3770/4885ALDH1A1 4705/4885 |
| US-20230355678-A1 | METHODS FOR IMPROVING T CELL EFFICACY | ICOS, IL2, CD4 | HPGD 1404/4885MEN1 4168/4885ALDH1A1 3596/4885 |
| US-11723923-B2 | Methods of preparing T cells for T cell therapy | IL15, CD4, IL2 | HPGD 2959/4885MEN1 3680/4885ALDH1A1 3834/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.